full
without
#666666
http://www.aurorabiomed.com/wp-content/themes/aurora-clean/
http://www.aurorabiomed.com/
#0066FF
style2

Speaking Program & Schedule 2016

Speaking Program Schedule

Please download: Preliminary Program

*Subject to change

Invited Guests (Listed in no particular order)

 

Guest Institution & Title Presentation Topic
 Qi-min Zhan Member of the Chinese Academy of Engineering (CAE),  Vice President of the Chinese academy of medical sciences, vice president of Peking Union Medical College, director of Peking University Health Science Center, director of State Key Lab of Molecular Oncology, awarded as “Changjiang Scholar” by Ministry of Education, winner of National Science Fund for Distinguished Young Scholars. Now on the board of the Chinese society of microcirculation and Chinese Anticancer Association. He is engaged in oncomolecularbiology and translational medicine for long time. TBA
 Hai-lin Zhang Vice president and Dean of Hebei Medical University, director of Pharmacological Division of Basic Medical College and Chair of 4th Ion Channel Conference. Awarded as Hebei Scholar, winner of National Science Fund for Distinguished Young Scholars and hosted many projects such as International cooperation project supported by NIH, projects supported by the Special Program for Key Basic Research of the Ministry of Science and Technology, National Natural Science Foundation, subjects sponsored by the Ministry of Education of China and so on. He is mainly engaged in relation between the structures and functions of ion channels, cellular signal transduction and the regulation mechanism of ion channel researches.
 Meng-feng Li Vice President of Sun Yat-sen University, Dean of Zhongshan School of Medicine, Distinguished Professors of medical microbiology in Cheung Kong Scholars, member of the subject consultative group of State Council Academic Degree Committee. He has been engaged in the researches and teaching of Molecular virology and Molecular Oncology, and devoting himself in knowing the relationship during pathogenic infection, inflammation course and oncogenesis to clarify the signal control mechanism and clinical significance, with the supports from NIH and others of the federal government and private foundations, China’s key state science and technology projects, Natural Science Foundation of China(NSFC), 863 Program, 973 Program and so on. Non-coding RNA and modulation of oncogenic signaling
 Yan Xu Vice Chair for Basic Research, Department of Anesthesiology; Professor of Anesthesiology, Pharmacology & Chemical Biology, Structural Biology, University of Pittsburgh.

He is interested in researches in Gene and stem cell therapy of global cerebral ischemia after cardiac arrest, Neurogenesis and angiogenesis in adult brain, Molecular and cellular basis of consciousness (approaching from unconsciousness to consciousness) and so on.

Designer Channels to Combat Painful Bladder Syndrome
 Hua-liang Jiang Director and Professor of Shanghai Institute of Materia Medica Chinese Academy of Sciences. Member of “Biological and Pharmaceutical technology” Panel of 863 Program of Ministry of Science and Technology, member of “Based on the signal transduction process research of small molecule probe” Panel of Major Research Project of the National Natural Science Foundation. Also served as Editorial Board Member of Journal of Medicinal Chemistry, ChemMedChem and 5 other international journals. He has been indicated in pharmaceutical foundation and new drugs R&D, to develop new strategy and methods of creative drugs, discovery and optimization for leading compounds, regulatory mechanisms of drug targets and so on through the cross of multi-disciplinary.
Annarosa Arcangeli Annarosa Arcangeli is full professor of General Pathology at the Univesity of Florence. She got her M.D. degree in 1981, the specialization in Hematology in 1984 and the PhD in 1989. Since more than thirty years Prof. Annarosa Arcangeli has been involved in studies aimed at determining the biophysical aspects of cancer. She started her studies defining the biophysical aspects of leukemias, then moving her studies to The paper “A novel inward-rectifying K+ current with a cell cycle-dependence governs the resting potential of neuroblastoma cells. J.Physiol., 489, 455-471,1995, was the first paper showing the role of a K+ channel in tumor cell cycle regulation. Afterwards, Prof. Arcangeli defined the role of hERG1 channel in cancer establishment and progression, integrating biophysical, biomolecular and genetic approaches. Thanks to Prof. Arcangeli studies, hERG1 can nowadays be considered an oncological target. The patent 11075PTWO/Dz: “HERG1 and GLUT1 in colorectal cancer” further translates to the clinical setting the findings published in Lastraioli et al., Canc. Res., 2004, Lastraioli et al., Transl. Oncol., 2012. Finally, Prof. Arcangeli has reached the demonstration of a functional and physical association between different ion channels and integrin receptors in cancer cells. These findings are reaching the translability thanks to the development of single chain diabodies, targeting the molecular complex constituted by hERG1 and b1 integrin in cancer cells. A novel perspective in personalized medicine: exploiting ion channels for cancer patients’ stratification
William Albert Catterall Professor and Chair of University of Washington Department of Pharmacology. American pharmacologist and neurobiologist, who researched ion channels. He served as professor at University of Washington School of Medicine in Seattle, Washington. He has been a fellow of the American Association for the Advancement of Science since 2010. In 2003, he received the 16th annual Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience Research, in recognition of his pioneering research into sodium and calcium channel proteins. In 2008, he was elected a Foreign Member of the Royal Society. In 2010, he won Gairdner Foundation International Award. The receptor sites for sodium channel and calcium channel blocking drugs at atomic resolution
 Duan-qing Pei President of Guangzhou Institute of Biomedicine and Health, Chinese Acedemy of Sciences, Distinguished Professors in Cheung Kong Scholars of Tsinghua University, Top ten scientific and technological innovation in 2015, elected as co-opted preliminary list of candidates of academician of Chinese Academy of Sciences. Dr. Pei is the leading figure of pluripotent stem cells and regenerative medicine, who was the first scientist in the world to get a mature organ with induced pluripotent stem cells, in order to struggle to aging and diseases of human beings. The Mechanism and Strategy of iPSCs reprograming
 Gong Chen Distinguished Chair Professor at Penn State (Verne M. Willaman Chair in Life Sciences), whose work focuses on brain repair after injury and neurodegenerative disorders. He pioneered an innovative in vivo reprogramming technology, converting reactive glial cells directly into functional neurons insideadult mouse cortex.This seminal work was published in Cell Stem Cell (Guo et al., 2014) and selected as one of the BEST of 2014 articles,because of its revolutionary approach in brain repair without externalcell transplantation. He published many research articles in world leading journals including Cell Stem Cell, Nature Communications, PNAS, Journal of Neuroscience, Nature, Cell, andreceived the prestigious Zenith Fellows Award by Alzheimer’s Association Brain Repair:

Reversing Glial Scar Through in vivo Reprogramming

Arthur M. “Buzz” Brown Founder and CEO of ChanTest Corporation, an ion channel company specializing in drug discovery and safety services. He is Adjunct Professor of Physiology and Biophysics, School of Medicine, Case Western Reserve University. He has more than 30 years of experience in ion channel structure-function relationships and their associations with human health. His lab first applied liquid ion exchanger ion-selective microelectrodes to single cells, showed that the human ether-à-go-go-related gene potassium channel was the molecular target for lethal arrhythmias associated with noncardiac drugs, and established that noncardiac drugs could also produce lethal arrhythmias by inhibiting ion channel trafficking. He holds eight patents on ion channel methodology and application of ion channel pharmacology to therapeutics. He received the Safety Pharmacology Society (SPS) Distinguished Service Award at the 13th SPS Annual Meeting in Rotterdam, The Netherlands.
 Balwant S. Tuana Professor of department of Cellular and Molecular Medicin, University of Ottawa, scholar of the Canadian Heart and Stroke Foundation and received a Career Investigator Award from the Heart and Stroke Foundation of Ontario. He is a coleader of the Heart Failure Cluster in the Ottawa region and has contributed to building collaborations in the cardiovascular community. He chaired the Senior Research Peer Review Committee of the Canadian Heart and Stroke Foundation and serves on national and international peer review committees of major funding agencies. His research has led to the identification of several novel genes in the human genome, which encode important proteins that are impacting various areas, including development and muscle as well as neuronal and cardiovascular function.
 Damian Doherty Chief Editor of the Journal of Precision Medicine, which is the world’s first print publication to discuss the key global issues surrounding this rapidly evolving landscape, connecting both ends of the life science continuum – the compelling discoveries being realised in molecular research with the critical needs of the patient in the clinical setting. He ever served on many well-known media magazines such as DRUG DISCOVERY WORLDIndependant Magazines and so on.
 Zhi-yuan Li Principal Investigator & Professor of South China Institute of Stem Cell & Regenerative Medicine, GIBH. In 2009 he was selected as “Hundred Talent Plan” of Chinese Academy of Sciences. He has published more than 60 papers on SCI, 7 academic monographs (including chapters and sections), 26 patents (12 of them has been authorized). Now he takes on more than 10 projects from 973 Program, NCFC, Guangdong Province, Foshan City etc, with more than 30 million funds. He serves as editors of Scientific Reports (Nature Publishing Group)、Journal of stem cells and clinical practice、Journal of Neurorestoratology and scientific board committee of international ion channel retreat. He is interested in researches in ion channels and neural differentiation of stem cells. Investigation of Nav1.1 Mutation Effect and Epileptic Mechanism using Patient iPSCs
Jian-cun Zhang Principal Investigator of Guangzhou Institute of Biomedicine and Health, Chiese Academy of Sciences. He is interested in design and syntheses of novel antiviral and anticancer agents, bioactive natural product total syntheses and modifications, new synthetic method development and process development for important molecules.

 

The Strategy of Drug Development on Calcium Channels
 Guang-yin Xu Vice Dean of institute of Neuroscience, distinguished professor, Soochow University. He has been long interested in the field of chronic pain, especially the visceral pain in functional Gastrointestinal disorders. He established an independent laboratory of Translation Pain Medicine and awarded a number of scientific research funds, including the NIH and NSFC fundings. The main research findings have been published in international top-tier Journals such as PNAS, Journal of Neuroscience, Gastroenterology, Diabetes, Pain, etc. As the first author and/or the corresponding author, he has published more than 50 peer-reviewed articles in he international top-tier SCI journals. Now he serves on Chinese Neuroscience Society, Chinese Physiological Society, Pain Society of Jiangsu Province, Jiangsu Talents Association, etc. Targeting purinergic P2X receptor signaling for chronic pain therapy
 Joseph W.O. Tam Chairman and Chief Executive Officer at DiagCor Bioscience Incorporation Limited, Consultant of Pangenia Life Science Limited. Dr. Tam is a research pioneer with over 30 years of teaching and research experience in the biotechnology and diagnostics sector. He is the Founder and President of the Hong Kong Biochemistry Association. Also he is a visiting Professor at UCSF, Baylor Medical College and Medical College of Georgia, Scientist of National Institute of Health, Associate Professor and Honorary Associate Professor of Medical Faculty of Hong Kong University. With the support of UNESCO, Professor Tam organized and trained the first group of scientists in China and Asia Pacific Regions on recombinant DNA research in 1983. During his years of teaching and research at HKU, Professor Tam invented and patented the “flow-through hybridization” technology. The Paradigm Shift of Laboratory Test: NGS vs Precision Medicine
Enders Kai On Ng Dr. Ng oversees Pangenia’s laboratory operations and research. He has over 15 years of molecular diagnostics and pathology experience. His research is mainly focused on assay development for capturing novel biomarkers of DNA and RNA including microRNA in blood for diagnosis and prognosis of cancer. Professor Ng has published over 100 review articles and peer-reviewed journals. In addition to his leadership role at Pangenia, he is also a Fellow at The Royal College of Pathologists of Australasia, Appointed Assessor for laboratory accreditation, and Honorary Assistant Professor at The University of Hong Kong. Development and Clinical Utility of Liquid Biopsy Cancer Testing
 Li Zhang Medical Officer, Laboratory for Integrative Neuroscience, NIAAA/NIH. He is the neuropharmacology exper, who is engaged in separating opiate therapeutics from major side effects of alcohol and other drugs of abuse with combined technologies of molecular biology, biochemistry, electrophysiology, etc. TBA
 Xian-guo Liu Professor and director of department of physiology in Zhongshan School of Medicine, director of Pain Research Center of Sun Yat-sen University (Guangzhou). His research is focused on peripheral and central mechanisms of chronic pain. In recent years he has investigated how activated glial cells and over-expression of cytokines lead to chronic pain, memory deficits and depression. He discovered long-term potentiation (LTP) of C-fiber evoked field potentials in spinal dorsal horn, which is now considered as a synaptic model of pathological pain. He has published more than 70 papers, which have been cited for  more than 3000 times. Now he is presindent of the Society for Neuroscience in Guangdong Province. He has reviewed the articles for Science, Journal of clinical investigation, Molecular Neurobiology, Brain research, Brain, Behavior, and Immunity, Brain research Bulletin, Journal of Neurophysiology, Neuroscience letter etc. Bulleyaconitine A Preferably Blocks Voltage-gated Sodium Channels of Dorsal Root Ganglion Neurons in Neuropathic Conditions
 Xiao-liang Wang President of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, and director of National engineering center for new drug development. He also serves on the Chinese Pharmacological Society, Professional committee of biochemical and molecular pharmacology, Chinese Pharmaceutical Association, etc. He built the patch clamp (ion channel researches) laboratory in early stage and made outstanding achievements. Dr. Wang has been active on forefront of pharmaceutical and new drug researches. At the same time, he is the chief editor of Acta Pharmaceutica Sinica, Consulting Editor of Naunyn-Schmiedeberg’s Archives of Pharmacology and associate editor of Journal of Alzheimer’s Disease. TBA
 Ling Chen Executive Deputy Director of State key laboratory of respiratory diseases, professor of Guangzhou Medical University, Distinguished Fellow & Founding director of GIBH, professor and director of University of Science and Technology of China. His research is involved in frontiers of biomedicine, including pathogenesis and vaccine researches of cancer, HIV, and other viral diseases. The researches have been published on NatureJournal of Clinical InvestigationCancer ResearchJournal of VirologyVaccine,etc international academic journals, and more than 10 international patents for inventions have been declared. Proton channel activity of influenza virus matrix protein 2 (M2) contributes to autophagy arrest
 Xing-jie Liang Deputy Director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and a principal investigator at Division of Nanomedicine and Nanobiology, National Center for Nanoscience and Technology of China. His research interests are in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vivo, and novel strategies to increast therapeutic effect on cancers and AIDS. Also he is serving on editor board of Biophysics Reports, Biomaterials, ACS Nano, Current NanoscienceTheranosticsBiomaterials Research and etc.

 

Nanotechnology Developed for Tumor Precision Treatment
 Ke-wei Wang Endowed ChangJiang Professor and the Dean of School of Pharmacy at Qingdao University, and serve as a Chair of the Department of Molecular and Cellular Pharmacology at Peking University School of Pharmaceutical Sciences. The overall research in his lab is directed towards understanding structure and modulation of ion channels, and identification and validation of ion channel targets and their modulators that have therapeutic potential for treatment of neuropsychiatric disorders such as pain, epilepsy, schizophrenia, stroke and depression. And he is also CEO and chairman of Qingdao Haiwei Biopharm Co. Ltd.. Identification of novel bioactive molecules from natural products targeting TRP channels for therapeutic potential
 Xiao-na Du Professor, Dept. Pharmacology, Hebei Medical University. Dr. Du has been engaged in ion channel researches since her PhD, and has been the visiting scholar of Leeds University and Health Science Center of Texas University. She mainly focuses on the physiological and pathological significances of ion channels and the regulation of neuronal excitability, especially in the relationship between the primary sensory ganglion DRG and pain, in which she achieved outstanding results and published many articles on SCI journals such as J Biol Chem, Brit J Pharmacol, MolPain, Plos one, Curr Neuropaharmacol, Pain, etc as the author/correspondence author. Peripheral somatosensory ganglia as a novel target for pain relief
 Zhan-feng Jia Professor, Dept. Pharmacology, Hebei Medical University. He had ever been to the university of Cincinnati as the postdoctoral fellow. His researches are focusing on the ion channels and signal transduction, especially in the molecular regulation and physiological and pathological significance targeted to ion channels with technologies of electrophysiologic techniques, molecular biotechnology and cell biology, including the function and regulation in neuralgia and inflammatory pain of M/K7 channel, the function and regulation in meditation to light touch, touch and pain of Piezo/MA channel, and so on. His research results have been published on academic journals such as Journal of Neurosci, Journal of General Physiology, Pfluger Arch, Mol Brain, Mol Pharmacol, etc. Regulation of Piezo2/mechanically-activated ion channel by static plasma membrane tension
 Nikita Gamper Professor of Neuroscience in School of Biomedical Sciences, University of Leed. His research focuses on the plasma membrane of cells, specifically the ion channels that regulate cellular excitability. Ultimately, Dr. Gamper’s research group is investigating how regulatory dysfunctions in ion channels affects peripheral pain-sensing neurons. As the first or corresponding author, he has published more than 50 articles on J Neurosci, PNAS, Nature Protocols, Cell. Physiol. Biochem, J. Biol. Chem, Mol. Biol. Cell, EMBO J, Pain, Sci Signal, Current Neuropharmacol, Current Drug Targets, Nat. Rev. Neurosci and other international journals. Also he published 6 monographs as the first or co-author. Substance P: an odd player in a painful game
 Ying-ji Li General manager of ICE Bioscience Inc., high-quality overseas professional in Beijing, distinguished expert. Dr. Li has been engaged in cardiovascular electrophysiology and pharmacology, especially in the researches in ion channels in hearts, ion channel drug screening, and he is specialized in establishment of drug screening methods and projects of multiple channels like NaV, CaV, BKCa, KCNQ, TRPV, TRPC, GABA, etc. Besides, he is also good at drug screening from Chinese traditional medicine and natural chemical compounds, as well as the regulation mechanism of ion channels in PAH. Dr. Li had ever been to the Medical University of Graz as a postdoctoral fellow. Moving from hERG to CiPA – Evolution of preclinical cardiac assessment and ICE’s practices
 Yuk-lam Lo Honorary chairman of Hong Kong Biotechnology Organization, Chairman of Hong Kong Chinese manufacturers association of industry and science and technology committee, Independent director of ShangPharma, Vice president of Sinovac Biotech Ltd., Adjunct professor of Department of Biochemistry (Medicine and Science), CUHK. He was the president of Pacific Rim, PerkinElmer Life and Analytical Sciences.
 Hai-long An Deputy director of molecular biophysics key laboratory of Hebei Province, deputy director of Institute of Biophysics, Hebei University of Technology. He is engaged in the researches in the relationship between structures and functions of ion channels, ion channels and diseases, and molecular design of drugs targeted ion channels. He has published up to 40 articles on academic journals such as Scientific Reports, Journal of Biological Chemistry、British Journal of Pharmacology, PLoS ONE, Journal of Membrane Biology, etc and 30 of them have been collected by SCI. Identification of Weak interactions which determine gating of Kir2 channels
William Wei-Guo Jia He is a senior researcher and associate prof (tenure) of neurosurgery at UBC. He has won the Canadian Institutes of Health Research Scholar Award . As the chief scientific advisor at the Shanghai Innovative Research Center of Traditional Chinese Medicine (SIRC-TCM) and the chief scientist at the Connaught Jian biotechnology company, he was among the first to use genetically engineered human herpes virus to treat cancer in Canada . Back in 2001 , his research and development of oncolytic viruses was approved to enter into clinical trials. He has also won the Petro Canada Young Inventors Award in 2007. Oncolytic virotherapy as a better immunotherapy for cancer
 Chun Lin Head of department of physiology and pathology physiology, head of laboratory of pain research, Fujian Medical University. Dr. Lin is also the member of Society for neuroscinece, member of World Institute of Pain, committee member of CASP, executive director of Fujian physiological society, standing committee member of CASP Fujian branch. She is focusing on the researches in neurosciences, especially in the molecular regulation of signal transduction in chronic visceral pain, and the mechanism of acupuncture analgesia. Peripheral HCN channels participate in chronic visceral hypersensitivity
 Shao Li Professor of physiology in basic medical college, Dalian Medical University, councial member of Aging and alzheimer’s professional committee of Chinese Pharmacological Society, secretary of physiological branch of Dalian Medical Association, member of Chinese Society of Neuroscience, member of American Society for neuroscinece. Dr. Li also serves as guest reviewers of international magazines such as Medical Science monitor ,Evidence-Based Complementary and Alternative Medicine, etc. Dr. Li’s publishment was elected as SCIENTIST AWARD of Singapore. Her researches expend from ion channels and nervous system diseases, zoom optical fiber optical tweezers and voltage dependent sodium channels to the development of scorpion venom drug. Suppress sodium channel activity as a new potential therapeutic target for Alzheimer’s disease
 David Deng Founder, president and CTO of ArdentBiomed, principal scientist of NGS of Da’an Gene. Dr. Deng served as senior researcher in Agilent Technologies to develop DNA Microarray and Microfluidics, leading to the first clinical diagnostic product in Agilent. He also served as R&D director/vice president of Verinata/Artemis Health Inc. to develop NIPD and CTC detection technology, R&D Associate Director of Life Tech / Ion Torrent to develop reagents of NGS,Ion PGM. Microfluidics and Next Generation Sequencing in the molecular diagnosis of cardiovascular diseases
 Jiang-hong Ye Professor of Anesthesiology, Pharmacology & Physiology, Rutgers -RHBS New Jersey Medical School. He is interested in the researches in the role of ion channels of the nervous system in anesthesia and Aalcoholism. Now he is on the editorial boards of Int J Physiol Pathophysiol Pharmacol (IJPPP)、The Open Journal of Neuroscience and ad hoc reviewer for 46 American and international journals. During 2011-2015, he is the member of the Neurotoxicology and Alcohol Study Section, NIH. Extrasynaptic Glycine Receptors of Rat Lateral Habenula Neurons: a Therapeutic Target for Ethanol-Intake and Withdrawal-Induced Pain
 Zheng-xiong Xi Senior Associate Scientist , Intramural Research Program of National Institute on Drug Abuse, NIH. His research has been focused on brain mechanisms underlying drug reward and addiction and medication development for treatment of drug addiction. His work related to brain dopamine D3 receptors, DA transporters, metabotropic glutamate receptors, GABA receptors and endocannabinoid CB1 and CB2 receptors has led to up to 100 publications, including many of them published in Nature Neuroscience, PNAS, Journal of Neuroscience, etc. Nanomedicine: A new approach for treatment of drug addiction
 Kan Deng CTO of Beijing Dashuyida Science and Technology Ltd .. He got the PhD of Robotics of computer college in Carnegie Mellon University. During his study in CMU, he was selected as the representative to participate America’s national association of artificial intelligence robot contest and got the first prizes in multiple events and the group points in second. He ever served in Oracle and Telenav. Apply deep learning technology to implement computer doctor
 Yong Wan Professor in department of cell biology, tenured professor of Hillman Cancer Center, University of Pittsburgh. He got his PhD in Cornell University and postdoctoral experiences in Havard University. Research interests from cell cycle control to genomic integrity with a particular focus on the role of ubiquitin-proteasome system (UPS) in the individual cellular system. As the first author or corresponding author, he has published up to 20 research articles on internatioanl academic journals, such as Nature, Nat Commun, PNAS, Mol Cell, J Biol Chem, etc. Targeting posttranslational modifications in genome stability and carcinogenesis
Lin Zhang Professor of pharmacology and chemical biolog, Hillman Cancer Center, University of Pittsburgh. His researches focus on Cancer Pharmacology, Signal Transduction and Drug Discovery. He has published up to 96 articles on research journals such as Science, Cell, Nature Genetics, Molecular Cell, PNAS, Cancer Research, etc and 40 papers on SCI journals in recent five years. Besides, he is the invited reviewers of ScienceMolecular CellPNASEMBO J.. Dr. Zhang has been the overseas judges as NIH, Yangtze River Scholar and key projects of NFSC, and get the financial fund up to 8 million dollars. Also, he gets awards such as General motors (GM) cancer research scholar award, overseas outstanding youth and so on. His creative researches include the development of SAGE & PEP gene which is leading to 3 patents for invention, the development of PUMA gene and discovering how PUMA、SMAC, Bax and p53 inducing apoptosis. Genetic basis of resistance to targeted therapies in colorectal cancer
Jian Yu Dr. Yu is a Professor of Pathology and Radiation Oncology at University of Pittsburg School of Medicine.  Dr. Yu obtained her Bachelor’s degree in Chemistry from Sichuan University, and Doctoral degree in Human Genetics and Molecular Biology from Johns Hopkins University.  Dr. Yu made seminal contributions to p53 biology by defining p53 transcriptome and identifying PUMA as a novel Bcl-2 family member and the major mediator of p53-dependent apoptosis in a variety of cell types.  Her recent work focuses on cancer driver-regulated cell killing mechanisms and their therapeutic exploration for selective elimination of colon cancer cells and protection of normal intestinal stem cells.  Dr. Yu has published over 80 research articles with over 10,000 citations, including ones in Cell, Nature, Science, Molecular Cell, Cell Stem Cell and PNAS.  Her work has been supported by NIH and private foundations. Intestinal stem cell protection during cancer treatment
Pei Tang Professor of Anesthesiology, Pharmacology & Chemical Biology, and Computational and Systems Biology, University of Pittsburgh School of Medicine. Dr. Tang has integrated multiple biophysical approaches, including NMR spectroscopy, X-ray crystallography, and electrophysiology, to determine structures and dynamics of pentameric ligand-gated ion channels and to understand the functional modulations of various low affinity drugs on these channels. She has published over 100 peer-reviewed original research articles. New insights into structures of pentameric ligand-gated ion channels
Zhou Wang Director of Urological Research, Department of Urology, the Co-Director of the Prostate and Urologic Cancer Program of the University of Pittsburgh Cancer Institute and a member of the Cellular and Molecular Pathology Graduate Training Program. In addition, he is the distingushed professor of Translational Medicine Research Center of Guangxi, and the first entrant selected into Innovative Short-term Projects of the Thousand Talents program. Dr. Wang ever chaired SBUR during 2011-2012. As the first/correspondence author, he has published more than 100 articles on multiple academic journals like Proc Natl Acad Sci, Cancer Res, J.Biol.Chem, Dev Biol, Anal Biochem, Endocrinology, Prostate, etc. Besides, he hosted multiple major research projects from NIH, DOD, etc, and was invited into program committee. Targeting androgen receptor in prostate cancer
Shi-yuan Cheng Professor of Neurology, The Ken and Ruth Davee Department of Neurology, The Ann and Robert H. Lurie Comprehensive Cancer Center, Center for Genetic Medicine at Northwestern University Feinberg School of Medicine. He is affiliated with the Northwestern Brain Tumor Institute. His research interests focus on the molecular mechanisms of human cancer tumorigenesis, progression, invasion, metastasis, and angiogenesis. He received a Zell Scholar award by Zell Family Foundation & The Ann and Robert H. Lurie Comprehensive Cancer Center, at Northwestern. A Kimmel Scholar award by Sydney  Kimmel Cancer Foundation, a V Scholar by V Cancer research fund, A Research Scholar Award by American Cancer Society, a Career Development Award by Breast Cancer Research Program, US Army Research Program and an Innovation Award by PNC Bank Foundation. Besides, he was invited to numerous grant review panels of US NIH, Breast Cancer Research Program of US Army Research Program, the Susan Komen foundation, United Kingdom Medical Research, Cancer Research UK, Canada’s national innovation foundation, Israel national medical research foundation,  Singapore national institute for medical research foundation and others. Dysregulated Signaling in Human Brain Tumors
Yu Jiang Associate Professor of Chemistry and pharmacology, University of Pittsburgh. He’s also the member of multiple associations, such as American College of Pharmacology, Society of Genetics, Society for General Microbiology, Society for Biochemistry and Molecular biology. Dr. Jiang was invited as peer reviewers for academic journals like Cancer Research, Drug Discovery Today, EMBO J, FEM Yeast, Gene & Development, J Biol Chem, Mol Biol Cell, Molecular Carcinogenesis, Mol Cell Biol, Molecular Endocrinology, Molecular Pharmacology, PNAS, Yeast, etc. Besides, he was also invited to the adjudication panels of United States-Israel Binational Science Foundation, National Science Foundation, NIH(Challenging grants). Dr. Jiang’s laboratory is interested in intracellular signaling pathways governing cell growth and metabolism. Cilium and Tumor Suppression
Dandan Sun Professor of Neurology, University of Pittsburgh Medical Center,UPMC. Her laboratory is interested in understanding the role of ion transporter proteins (sodium-potassium-chloride cotransporter, sodium/proton exchanger, and sodium/calcium exchangers) in ionic dysregulation and neurodegeneration associated with stroke and hypoxic ischemic encephalopathy. Besides, she has been a principal investigator for multiple NIH/NINDS R01 grant awards and served on multiple study sections of NIH/NINDS and peer review groups of the AHA. Dr. Sun has published up to 60 articles on SCI Journals of which IF are higher than 5 points, and 19 monographs. And she has been the Ad Hoc Reviewer of multiple journals such as Nature, Stroke, etc. WNK3-SPAK/OSR1-NKCC1 Signaling Pathway in Ischemic Stroke
Dexi Liu Professor and Department Head of pharmacology and biomedicine,University of Georgia. He has published more than100 articles on internatial academic journals and hosted multiple science and technology projects of NIH. Besides, he has been the editorial board members of many journals such as AAPS Journal, Bioscience Reports, Molecular Therapy, Gene Therapy, Pharmaceutical Research, Molecular Therapy-Nucleic Acids and Molecular Therapy-Methods & Clinical Development. Hepatic tumorigenesis by genomic editing using CRISPR/Cas9 and sleeping beauty transponson systems
Ming Qi Professor of Pathology and Pathophysiology in School of Medicine of Zhengjiang University, Director of Zhejiang University Center for Genetic and Genomic Medicine, Distinguished Professor of Watson Genomics Institute, Adjunct Researcher of Beijing Genomics Institute of CAS. Besides, he is also the senior fellow of American College of Medical Genetics, distinguished member of the branch of HUGO, CAP Inspector, Chinese representative of Genetic diagnosis international standards committee of experts of OECD, consultant of Genetics and genomics center at harvard medical school. His researches are interested in the mechanism how gene mutations cause diseases and individual treatment, in particular the action to drugs, food, environment of different mutations. Cardiac arrhythmias and neuromuscular channelopathies
Tao Cheng Prof. Tao Cheng is currently the Scientific Director of Institute of Hematology & Blood Diseases Hospital, Head of the State Key Laboratory of Experimental Hematology, and Chairman of Department of Stem Cell and Regenerative Medicine at the Chinese Academy of Medical Sciences & Peking Union Medical College. Prof. Cheng has made important contributions to our understanding on cell cycle control, survival, reprogramming and malignant transformation of hematopoietic stem cells. He has published more than 150 research articles, invited reviews and book chapters in experimental hematology and stem cell biology. He is the founding president of the Chinese Association for Blood Sciences (CABS) and holds leadership positions in several professional societies. He has been an editorial board member or associate editor for more than 10 international journals such as Blood, Leukemia and Experimental Hematology. ‘Waterloo’: when normal blood cells meet leukemia
Yi-fan Dai Distinguished Professor of Thousand Talents program, chair professor of “Cheung Kong Scholar”, Director of Jiangsu key laboratory of Xenotransplantation, Distinguished professor of Nanjing Medical University. Dr. Dai’s researches are focused on the genetically modification and cloning of pigs for xenotransplantation and applications of large animal model in human diseases. His results have been published on Science and Nature, and selected as Top 100 most important scientific news on DISCOVERY Magazine twice (No. 36 in 2002 and No. 38 in 2006). In 2002, Dr. Dai won Fujisawa Young Scientist Award of Transplantation. Producing Personalized Human Organs in Pigs
Xiao Xiao Fred Eshelman Distinguishe professor of Gene therapy, University of North Carolina at Chapel Hill. Xiao’s work on muscular dystrophy, especially the Duchenne muscular dystrophy, has received international recognition. His paper published in 2000 on gene therapy for DMD was broadly covered by the media, and his groundbreaking work has been developed into the first gene therapy phase I clinical trial for DMD in the United States. In 2005, his paper on systemic gene delivery for muscular dystrophy was recognized by the National Institutes for Health as a major scientific advancement, and was selected as one of the 100 top scientific stories in 2005 by Discover magazine. As an independent investigator, Xiao has published 58 peer-reviewed papers from 1998 to 2006. He is the inventor or co-inventor of twelve issued or pending U.S. patents and is also a member on a number of study sections at the National Institutes of Health. Tissue- and cell-targeted gene delivery and therapy for precision medicine
Xiang-Qun Sean Xie Associate dean for research innovation, school of pharmacy, University of Pittsburgh; Director/PI of NIH National Center of Excellence for Computational Drug Abuse Research; Charter member of the Science Board to the United States FDA, NIH Biophysics of Neural System(BPNS) Study section review panel. Also he is the professor of Dept of Pharmaceutical Sciences, Drug Discovery Institue, and Dept of Structural Biology, School of Medicine, and Joint Carnegie Mellon University/ Univ. of Pittsburgh Computational System Biology Ph. D. Program, School of Medicine, Univ. of Pittsburgh and Pitteburgh Supercomputing Center. He focuses his research on target identification ans system pharmacology and invention discovery patents. The innovative work was achieved by his developed GPU-accelerated cloud computing TargetHunter machine-learning programs and diseases-specific chemogenomics knowledgebase. His recent work on Alzheimer’s disease specific chemogenomics database was on 2014 coverpage story of a top peer-reviewed ACS journal. The innovation work includes GPU-accelerated cloud computing TargetHunter program for drug target identification led him to received the 2014 AAPS Award for Outstanding Research Achievements. Precision System Pharmacology (PSP), an insightful precision medicinevia chemogenomics knowledgebase TargetHunter©
Qiming Jane Wang Associate Professor & Vice Chair, Regulatory Affairs, University of Pittsburgh. Targeting a novel androgen repressed pathway in prostate cancer therapy
Amal Kanti Bera Professor of Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences  Bhupat and Jyoti Mehta, Indian Institute of Technology Madras. His researches are involved in wide range of research projects exploring the structure, function and regulation of different ion channels, particularly channels that are associated with neurological and cardiovascular disorders. Our long-term goal is to target specific ion channels for treating stroke and heart diseases. He has published up to 40 articles on multiple international and indian journals. Besides, Dr. Bera serves as the editorial board member of Journal of PROTEINS AND PROTEOMICS (A journal of the Proteomics Society, India, PSI). Phytochemical for targeting acid sensing ion channels
Zun-fu Ke Director of Pathology at the First Affiliated Hospital of Sun Yat-sen University, professor of pathology and pathobiology, recommended candidate of 2015 Chang Jiang Scholars Program, executive chairman of 1st Precision Medicine and Molecular Diagnosis Summit in Guangdong. He has been engaged in the scientific and clinical researches of CTC. Right now he also serves on Tumor Molecular Diagnostic Committee of Guangdong Provincial Anti-Cancer Association, Molecular Pathology Quality Control Team in Guangdong Province, Breast Cancer Prevention Research in Guangdong Province. New progress and clinical application of circulating tumor cells (CTC) capture technology
Zheng-yu Cao Professor at State Key Laboratory of Natural Medicines, Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, China Pharmaceutical University. His researches is focusing on neuropharmacology and neurotoxicity. Dr. Cao has been hosting multiple projects, like NIH, NSFC, projects of Jiangsu Province, State key laboratory of natural medicine and so on. He has published up to 30 research articles on international media. Besides, he has been invited as editoral committee members of Genetic Disorders & Gene Therapy, International Journal of Stem Cell Research and Transplantation, Austin Journal of Allergy, etc, and peer reviewers of JPET, Toxicological Sciences, NeuroToxicology for long time. Modifiers of distinct Ion channels differentially modulate Ca2+ dynamics in primarily cultured rat ventricular cardiomyocytes
Yuko Sekino Head in Division of Pharmacology, National Institute of Health Sciences Validation study for the possible usage of human iPS-derived cardiomyocytes for the safety pharmacology : JiCSA activity
Takashi Yoshinaga Senior Principal Scientist, Global Cardiovascular Assessment, BA-CFU, Eisai Co., Ltd. Comprehensive in vitro and in silico torsadogenic risk assessment using multi ion channel data and multi-scale human heart simulator
Shouming Du PhD of Chemistry, New York University, Product Manager, FDSS, Hamamatsu TBA
Haoyu Zeng Principal scientist in Merck’s Department of Safety and Exploratory Pharmacology. He is the author/co-author of more than 12 manuscripts/book chapters and has presented at more than 10 scientific conferences. TBA
Weifeng Yu Senior Application Scientist, Biolin Scientific
Kazuya Tsurudome Senior Application Scientist, Biolin Scientific K.K. Automated patch clamp recordings from iPS-derived neurons
More……
default
Loading posts...
link
#6E787E
on
fadeInUp
loading
#6E787E
off
Back